Biotech · Private company
BioInvent International AB
Track this companyFree. Adds BioInvent International AB to your Dealase workspace and tells you when its record changes.
Clinical trials43 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline10
- AcalabrutinibPhase 2 · Indolent B-Cell Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- Autologous stem cell transplantationPhase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- BI-1206Phase 2 · Indolent B-Cell Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- BI-1808Phase 2 · Advanced MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- BI-505Phase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- BI1206Phase 2 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- High dose melphalanPhase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- Paclitaxel 80 mg/m2 weeklyPhase 2 · Advanced MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for InjectionPhase 2 · Advanced MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 2 · Indolent B-Cell Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)PHASE1_PHASE2 · RECRUITING · started Jan 25, 2021ClinicalTrials.gov NCT04752826 · fetched Nov 12, 2026
- A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsPHASE1_PHASE2 · RECRUITING · started Jun 29, 2020ClinicalTrials.gov NCT04219254 · fetched Nov 12, 2026
- A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHLPHASE1_PHASE2 · RECRUITING · started May 16, 2018ClinicalTrials.gov NCT03571568 · fetched Nov 12, 2026
- A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple MyelomaPHASE1_PHASE2 · TERMINATED · started May 1, 2016ClinicalTrials.gov NCT02756728 · fetched Nov 12, 2026